Small-molecule clinical trial candidates for the treatment of glioma

- Approximately 2% of all cancers are glioma, themselves the most common primary tumours of the central nervous system.
- Small organic molecules that are currently being assessed for the treatment of glioma in clinical trials are reviewed.
- Mechanisms of the most common compounds are either: protein kinase inhibitors; topoisomerase inhibitors; or tubulin inhibitors.
- Potential exists to exploit new mechanisms of action to treat this disease.